NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial

• click to rate

  Posted by Two Blokes Jun 6 - Filed in Stock - 9 views
  
  Novocure's PANOVA-3 trial shows that the TTFields combo boosts survival in pancreatic cancer, hitting the primary endpoint.